Sarkar K, Sadhukhan S, Han SS, Vyas YM (2015) SUMOylation-disrupting WAS mutation converts WASp from a transcriptional activator to a repressor of NF-κB response genes in T cells. Blood 126, 1670-82 26261240

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K76-sm - WASP (human) ▲

Modsite: CGAVCFVkDNPQkSy SwissProt Entrez-Gene Orthologous residues WASP (human): K76‑sm, WASP (mouse): K78‑sm, WASP (rat): K76‑sm Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, western blotting Disease tissue studied:  leukemia, T cell leukemia Relevant cell lines - cell types - tissues:  B lymphocyte, dendritic cell, HeLa (cervical), Jurkat (T lymphocyte), natural killer cell, T lymphocyte Cellular systems studied:  cell lines, primary cells Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBC9 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE UBC9 (human) co-immunoprecipitation SUMO LIGASE RANBP2 (human) co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes N-ethylmaleimede no change compared to control Downstream Regulation Effect of modification (function):  acetylation, molecular association, regulation Effect of modification (process):  signaling pathway regulation, transcription, altered Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays COMMD1 (human) Disrupts co-immunoprecipitation HDAC6 (human) Disrupts co-immunoprecipitation Comments:  induces hypoacetylation at H3K14, regulates NF-kB signaling

K144-sm - WASP (human) ▲

Modsite: FRALVQEkIQkRNQR SwissProt Entrez-Gene Orthologous residues WASP (human): K144‑sm, WASP (mouse): K146‑sm, WASP (rat): K144‑sm Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, western blotting Disease tissue studied:  leukemia, T cell leukemia Relevant cell lines - cell types - tissues:  B lymphocyte, dendritic cell, HeLa (cervical), Jurkat (T lymphocyte), natural killer cell, T lymphocyte Cellular systems studied:  cell lines, primary cells Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBC9 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes SUMO LIGASE RANBP2 (human) co-immunoprecipitation UBIQUITIN LIGASE UBC9 (human) co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes N-ethylmaleimede no change compared to control Downstream Regulation Effect of modification (function):  acetylation, molecular association, regulation Effect of modification (process):  signaling pathway regulation, transcription, altered Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays HDAC6 (human) Disrupts co-immunoprecipitation COMMD1 (human) Disrupts co-immunoprecipitation Comments:  induces hypoacetylation at H3K14, regulates NF-kB signaling

K147-sm - WASP (human) ▲

Modsite: LVQEkIQkRNQRQSG SwissProt Entrez-Gene Orthologous residues WASP (human): K147‑sm, WASP (mouse): K149‑sm, WASP (rat): K147‑sm Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, western blotting Disease tissue studied:  leukemia, T cell leukemia Relevant cell lines - cell types - tissues:  B lymphocyte, dendritic cell, HeLa (cervical), Jurkat (T lymphocyte), natural killer cell, T lymphocyte Cellular systems studied:  cell lines, primary cells Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBC9 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes SUMO LIGASE RANBP2 (human) co-immunoprecipitation UBIQUITIN LIGASE UBC9 (human) co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes N-ethylmaleimede no change compared to control Downstream Regulation Effect of modification (function):  acetylation, molecular association, regulation Effect of modification (process):  signaling pathway regulation, transcription, altered Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays COMMD1 (human) Disrupts co-immunoprecipitation HDAC6 (human) Disrupts co-immunoprecipitation Comments:  induces hypoacetylation at H3K14, regulates NF-kB signaling